BioSpace News Archive

Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, and Mundipharma today announced that the first patient has been dosed in its ReSPECT pivotal Phase 3 clinical trial evaluating the efficacy and safety of the company’s lead antifungal candidate, rezafungin, for the prevention of invasive f

Octant, Inc., a synthetic biology drug discovery company designing small molecule, multi-target drug leads for multifactorial diseases announced that it has raised $30 million in a Series A financing led by venture capital firm Andreessen Horowitz.

VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”), a multi-national epigenetics company that applies its Nucleosomics TM platform through its subsidiaries to develop simple, easy to use, cost-effective blood tests to help diagnose a range of cancers and other diseases, announced today the pricing of its previously announced underw

The Alliance for Regenerative Medicine (ARM), the international advocacy organization for the cell and gene therapy and broader regenerative medicine sector, announced that it will be holding its annual Legislative Fly-In today. This event, which has been remodeled to take place virtually, enables ARM members to advocate on Capitol Hill for legislative support of gene and cellular therapies and other regenerative medicines.

Parexel’s leading Real-World Evidence expertise combined with Microsoft’s innovative cloud technology will support physicians and researchers in better understanding and adjusting treatment in real-time

Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to utilizing proprietary non-viral gene engineering platform technologies to create next generation cell and gene therapeutics with the capacity to cure, today announced the first patient has been dosed in its Phase 1 clinical trial evaluating P-PSMA-101, its au

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the launch of RADICAVA ® (edaravone) JourneyMate ™ , a new program connecting people with amyotrophic lateral sclerosis (ALS) and their families to live nurse educational support, which can help answer questions about the disease and treatment options.

VigiLanz, a clinical surveillance company, today announced COVID Quick Start – a new solution that will enable hospitals to prepare for, prevent, and respond to the spread of COVID-19 and other respiratory viral illnesses. COVID Quick Start gives hospitals customizable real-time alerts and reports to manage viral outbreaks and exposures.

Precision NanoSystems to Prese CanSinoBIO will license in Precision NanoSystems’ proprietary RNA vaccine platform technology Precision NanoSystems will lead RNA vaccine formulation development CanSinoBIO will lead COVID-19 antigen design, pre-clinical testing and clinical trials TIANJIN, China and VANCOUVER , May 20, 2020 /PRNewswire/ - CanSino Biologics Inc. (Ca

Comet Bio announced today the successful completion of its randomized, placebo-controlled, crossover clinical trial evaluating the gastrointestinal (GI) tolerability and prebiotic effects of its Arabinoxylan Plant Fiber Extract, Arrabina™. Resu